Displaying 1 - 5 of 5 for Cancer - Myeloma
  • CHARKALL Study (H-23574)
    • Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL. The lymphoma, MM or CLL has come back or has not gone away after treatment. This is a gene transfer research study using special immune cells.
  • Multiple Myeloma Study (H-33837
    • The purpose of this study is to explore a drug combination alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
  • TACTAM Study (H-35626)
    • The purpose of this study is to find the largest safe dose of TAA-specific CTLs, to learn what the side effects are, and to see whether this therapy might help patients with multiple myeloma.
  • TACTASOM Study (H-35425)
    • This study uses special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy to treat patients with a solid tumor which has come back or has not gone away after treatment.
  • Treatment for Patients With Newly Diagnosed Multiple Myeloma (H-35330)
    • This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma.